New drug HBM7020 tested in humans for first time against autoimmune diseases
NCT ID NCT07649265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see if the drug is safe and how the body processes it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBM7020
What this could lead to
If safe, this could lead to a new treatment option for autoimmune diseases like lupus and rheumatoid arthritis.
What could go wrong
This is a very early Phase 1 trial with only 63 people, so safety and effectiveness are not yet known. Side effects like immune reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••